Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 3.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,687,610 shares of the company's stock after purchasing an additional 162,994 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.95% of Elanco Animal Health worth $56,767,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ELAN. Farther Finance Advisors LLC boosted its position in Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company's stock worth $49,000 after acquiring an additional 2,044 shares during the last quarter. Atria Investments Inc boosted its position in Elanco Animal Health by 57.9% during the third quarter. Atria Investments Inc now owns 56,613 shares of the company's stock worth $832,000 after acquiring an additional 20,760 shares during the last quarter. Venturi Wealth Management LLC boosted its position in Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company's stock worth $50,000 after acquiring an additional 1,601 shares during the last quarter. Versor Investments LP acquired a new position in Elanco Animal Health during the third quarter worth about $380,000. Finally, Aigen Investment Management LP acquired a new position in Elanco Animal Health during the third quarter worth about $173,000. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ELAN. Stifel Nicolaus decreased their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, February 21st. Leerink Partnrs raised shares of Elanco Animal Health to a "hold" rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They issued a "market perform" rating and a $14.00 price target for the company. Barclays dropped their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, UBS Group dropped their price target on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Elanco Animal Health has a consensus rating of "Hold" and an average target price of $15.17.

Remove Ads

Insider Buying and Selling

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the stock in a transaction on Tuesday, March 11th. The shares were bought at an average cost of $10.20 per share, with a total value of $102,000.00. Following the transaction, the director now owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Stock Up 1.5 %

Elanco Animal Health stock traded up $0.16 during mid-day trading on Friday, reaching $10.47. 4,680,857 shares of the company's stock were exchanged, compared to its average volume of 4,674,860. The company has a market cap of $5.18 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.50 and a beta of 1.44. Elanco Animal Health Incorporated has a twelve month low of $10.03 and a twelve month high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The company has a fifty day moving average of $11.46 and a 200-day moving average of $12.75.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the previous year, the business posted $0.08 earnings per share. Elanco Animal Health's revenue for the quarter was down 1.4% compared to the same quarter last year. Sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.